Novo Nordisk: drug shows weight loss in phase 2 trial.
(CercleFinance.com) - Novo Nordisk reported a weight loss of up to 13.
8% in people with obesity receiving its diabetes drug semaglutide in a phase 2 trial.
From a mean baseline weight of around 111 kg, a weight loss up to 17.8 kg was observed after 52 weeks of treatment at the end of the trial, which included 957 people with obesity.
By comparison, an estimated weight loss of 2.3% was achieved by diet, exercise and placebo alone, the Danish drugmaker said.
Novo Nordisk now expects a phase 3 programme to begin in 2018 will confirm these results.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
8% in people with obesity receiving its diabetes drug semaglutide in a phase 2 trial.
From a mean baseline weight of around 111 kg, a weight loss up to 17.8 kg was observed after 52 weeks of treatment at the end of the trial, which included 957 people with obesity.
By comparison, an estimated weight loss of 2.3% was achieved by diet, exercise and placebo alone, the Danish drugmaker said.
Novo Nordisk now expects a phase 3 programme to begin in 2018 will confirm these results.
Copyright (c) 2017 CercleFinance.com. All rights reserved.